Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Faulkner v. Acella Pharmaceuticals, LLC
Case Number:
2:22-cv-00092
Court:
Nature of Suit:
Racketeer/Corrupt Organization
Multi Party Litigation:
Class Action
Judge:
Firms
-
May 20, 2024
Ga. Judge OKs $5M Atty Fees In $41M Acella Thyroid Deal
A Georgia federal judge has signed off on a nearly $41.5 million class action settlement with Acella Pharmaceuticals LLC over faulty thyroid medication, while awarding the class attorneys another $5 million in legal fees courtesy of the pharma company.
-
May 01, 2024
Attys Say $5M Fee In Acella Settlement A Modest Proposal
Plaintiffs' attorneys who recently reached a $46.5 million class action settlement with Acella Pharmaceuticals LLC over faulty thyroid medication asked a Georgia federal judge Tuesday to sign off on their $5 million cut of the deal as a "presumptively reasonable" proposal.
-
February 07, 2024
Acella's $46.5M Drug Recall Settlement Gets Initial Signoff
A Georgia federal judge on Wednesday gave preliminary approval of a nearly $46.5 million settlement from Acella Pharmaceuticals LLC to end a class action alleging the company sold worthless thyroid medication to hundreds of thousands of Americans.
-
February 05, 2024
Proposed Class Action Settlement May Cost Acella $46.5M
A proposed agreement to end a class action over thyroid medication, after a U.S. Food and Drug Administration inspection found products with an active ingredient above and below label specifications, may cost Acella Pharmaceuticals $46.5 million.
-
July 11, 2023
Judge Calls Drugmaker's Bid To Strike 'A Bit Disingenuous'
Acella Pharmaceuticals can't escape a proposed class action over its recalled thyroid medication, a Georgia federal judge ruled, calling some of the company's assertions as to why the plaintiffs could never secure class certification "a bit disingenuous."
-
May 13, 2022
Pharmaceutical Co. Sued Over Recalled Thyroid Medication
Acella Pharmaceuticals is facing down a proposed class action in Georgia federal court over its recalled thyroid medication, which plaintiffs claim was released untested and caused them harm.